Introduction

Immune checkpoint inhibitors (ICIs) have marked a breakthrough in the management of a wide range of cancer types, leading to increased overall survival. However, this treatment is frequently associated with the onset of various immune-related adverse events (irAEs), including ICI-related diarrhea and colitis.¹ Current recommendations for patients with diarrhea or colitis grade 2 or higher (graded via CTCAE)² include the discontinuation of ICI and administration of immune suppressants (e.g. steroids or biologics), which may lead to worse outcomes in these patients.³ Therefore, alternative therapeutic strategies to manage irAEs are needed. The gut microbiota plays a pivotal role in the onset of gastrointestinal irAEs, but the role of its therapeutic modulation on these disorders is mostly unknown. ^4,5

Aims & Methods

Our aim was to evaluate the efficacy and safety of therapeutic microbiome modulation for gastrointestinal irAEs in cancer patients. We enrolled cancer patients affected by ICI-related diarrhea/colitis referred to our Microbiome Clinic from January 2023 to March 2025. After clinical evaluation, patients were stratified according to severity of diarrhea (graded via CTCAE)² and then received a microbiome-modulating therapy. Patients were followed-up for at least 8 week after the initiation of therapy. We collected data about patient demographics (age and gender), patient’s overall health status as assessed by the the Charlson Comorbidity Index (CCI)⁶, type of cancer, oncological therapy and its suspension, time in weeks from initiation of cancer therapy to onset of diarrhea, severity of diarrhea (graded via CTCAE)², time in weeks until resolution of diarrhea and resumption of oncological therapy

Results

We enrolled 42 patients in the study period (8 males, 34 females, mean age 58,3 years-old, mean CCI-index 5.8). All patients were treated with ICI (Pembrolizumab: n=25 , Dostarlimab: n=4, Nivolumab: n=4; Atezolizumab: n=3; Novulumab and Ipilumab: n=2, Cemiplimab: n=2; Mogamulizumab: n=1; Pertuzumab: n=1). Ten patients experienced G1 diarrhea (23,8%), 16 (38,1) G2, 15 (35,7%) G3 and one G4 (2,4%). As indicated by current European Guidelines³, 30 patients (71,4%) had to interrupt ICI due to diarrhea. Multi-strain probiotics were administered to 27 (64.3% ) patients, rifaximin to 22 (52,4%). Overall, 21 patients (50%) needed therapy with systemic steroids. Seven patients who experienced ICI-related colitis refractory to steroids and biologics were successfully treated with FMT. Twenty-eight patients (66.7% ) had a resolution of the diarrhea (G0) and 11 patients (26.2%) had diarrhea G1 at a mean time of 8 weeks. Upon resolution of diarrhea, nine of the 30 patients who had interrupted ICI (30%) were able to resume the treatment. None of the patients experienced any adverse event related to gut microbiota modulation as defined by CTCAE².

Conclusion

Therapeutic modulation of gut microbiota appears to be a promising safe and effective approach for treating ICI-related diarrhea and colitis. However, these preliminary findings need confirmation through more consolidated and well-designed studies.

References

1. Dougan M, Wang Y, Rubio-Tapia A, Lim JK. AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review. Gastroenterology. 2021;160(4):1384-1393. doi:10.1053/j.gastro.2020.08.063
2. Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas Dermosifiliogr. 2021;112(1):90-92. doi:10.1016/j.ad.2019.05.009
3. Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(12):1217-1238. doi:10.1016/j.annonc.2022.10.001
4. Wang Y, Wiesnoski DH, Helmink BA, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2018;24(12):1804-1808. doi:10.1038/s41591-018-0238-9
5. Wang T, Zheng N, Luo Q, et al. Probiotics Lactobacillus reuteri Abrogates Immune Checkpoint Blockade-Associated Colitis by Inhibiting Group 3 Innate Lymphoid Cells. Front Immunol. 2019;10. doi:10.3389/fimmu.2019.01235
6. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40(5):373-383. doi:10.1016/0021-9681(87)90171-8

Disclosure

G.I. has received personal fees for acting as speaker for Biocodex, Danone, Sofar, Malesci, Metagenics and Tillotts Pharma, and for acting as consultant and/or advisor for Ferring Therapeutics, Giuliani, Malesci and Tillotts Pharma. A.G. reports personal fees for consultancy from Eisai Srl, 3PSolutions, Real Time Meeting, Fondazione Istituto Danone, SinergieSrl, Board MRGE and Sanofi SpA personal fees for acting as a speaker for Takeda SpA, AbbVie and Sandoz SpA and personal fees for acting on advisory boards for VSL3 and Eisai. G.C. has received personal fees for acting as advisor for Ferring Therapeutics. All other authors have no conflicts of interest to disclose.

Introduction

Paneth cells (PC) are involved in the regulation of intestinal microbiota, and their function in intestinal lymph- and angiogenesis has been recently described. Uptake of dietary lipids is largely dependent on intestinal lymphatic vessels, and impairments in their density or function may result in significant depletion of lipids in the liver. In this study, we assessed the effects of PC deficiency in a model of metabolic dysfunction associated steatotic liver disease (MASLD).

Aims & Methods

We induced functional inactivation of PC in male and female mice (Sox9^lox/loxVilCre^ERT2) by intraperitoneal injection of 1mg/day of tamoxifen for three consecutive days. One week later, all mice, PC-deficient, and control littermates were randomly subjected to a high sucrose/fructose - high fat (60% lard) (HFD) or standard (SD) diet for 16 weeks. Intraepithelial leakage of FITC-albumin was measured in vivo using laser-probe endomicroscopy. Several tissues were harvested for histological examination, molecular biology analyses, and imaging mass cytometry (IMC). Fecal samples were collected at both the start and end of the experiment to assess intestinal dysbiosis and fecal fat content.

Results

All mice fed HFD gained weight compared to SD, but the weight gain in PC-deficient-HFD was significantly lower than in HFD-controls. Consistent with these findings, the severity of hepatic steatosis was significantly lower in PC-deficient mice compared to HFD-control. IMC of liver tissue revealed lower levels of collagen deposition and steatosis associated with fewer macrophages and neutrophils activation/infiltration in PC-deficient-HFD than in control-HFD mice. In vivo, microscopy showed a lower disruption of intestinal vascular barriers in PC deficient-HFD mice than in HFD controls. The intestinal expression of distinct lymphangiogenic genes (VEGFC, VEGFR3, Prox1) was reduced in the PC-deficient HFD or SD. Moreover, PC-deficient-HFD showed a higher level of fecal fat excretion than HFD controls. The alpha diversity of the fecal microbiota showed no significant differences based on gender or PC deficiency in the SD groups. Nevertheless, the beta diversity showed significant differences in PC-deficient fed SD after 16 weeks. Furthermore, we found significant alpha- and -beta diversity associated with decreased Bacteroidota and increased Firmicutes in HFD and PC-deficient mice.

Conclusion

PC deficiency attenuated the severity of steatosis and fibrosis in mice, suggesting their regulatory role on intestinal lymphatics contributing to the pathogenesis of MASLD. Thus, Paneth cells may represent a novel target for intervention in MASLD.

Introduction

Histological assessment in Inflammatory Bowel Disease (IBD) is often required with endoscopic diagnoses to establish disease activity. This is evident in patients where histological healing is a major therapeutic goal and when endoscopic healing can also exhibit microscopic disease. IBD can manifest in numerous landmark features which are structural and inflammatory related. Histological activity is determined through erosion/ulceration, architectural changes in tissue morphology, mucin depletion and presence of varied inflammatory cells the colonic crypts, Muscularis Mucosae (MM) and Lamina Propria (LP). Histological scoring systems vary in complexity and methodology and subject to discrepancies in inter-rater consensus. Our model aims to provide accurate measurements of key histological features in Ulcerative Colitis (UC) used in scoring systems as both a decision support tool for improving pathologist scoring alignment and sensitive quantitative metrics of inflammatory cells to evaluate disease activity.

Aims & Methods

We developed an ensemble of convolutional neural networks to identify cell types, tissue foreground, crypts, MM, and haemorrhage in H&E images of IBD biopsy data. Models were trained with expert-labelled annotations comprising 34,289 image-annotation pairs (80% training, 20% validation) from in-house and publicly available data. Model accuracy was assessed with 6,464 held-out image-annotation pairs from 26 Whole Slide Images (WSIs) from all sites of the large intestine commonly sampled during endoscopic investigation, while ground truth annotations were reviewed by GI-trained pathologists to certify accuracy. We used geospatial methods to derive boundaries of the LP from other predicted domains, associate cells to delineated regions, measure architectural changes and derive spatially differentiated metrics of inflammatory burden in 66 patients with confirmed UC.

Results

The AI model spatially differentiates and segments cell types and tissue compartments. This produces metrics for inflammatory cell counts in regions of interest such as crypts, LP, and MM. Goblet cell segmentation within crypts allows for measurement of mucin depletion. This can be visualized for pathologists where each inflammatory cell type across the WSI is represented as density metrics. Automated quantification of inflammatory cells across AI-identified tissue domains throughout the bowels of UC patients revealed large intra- and inter-patient variability.

Conclusion

Our AI model can measure histological healing by detecting architectural change, inflammatory cell number, goblet cell reduction and erosions and ulceration. This allows for metrics and visual overlays to assist with pathologist reading and quantifying changes in mucosal biopsies in a clinical trial setting which requires extremely sensitive tools only AI can provide.

Disclosure

DW/AM/RL/PA/PW and CL are employees at Perspectum Ltd. EF and RG are consultants for Perspectum Ltd. All other co-authors have no conflicts of interest to declare relevant to this work.

Introduction

We conducted a retrospective cohort study to evaluate the risk of serious infections in patients with Ulcerative Colitis (UC) initiating advanced biological or small molecule therapies

Aims & Methods

Using a large U.S. administrative, Optum Labs® database, we identified adult UC patients who initiated treatment with either tumor necrosis factor-α (TNF) antagonists (infliximab, adalimumab, and certolizumab pegol), IL-12/23 antagonists (ustekinumab), IL-23 antagonists (risankizumab), anti-integrin agents (vedolizumab), S1PR modulators (ozanimod), or Janus kinase (JAK) inhibitors (tofacitinib, upadacitinib) between 2016-2023. Eligible patients had at least one year of continuous insurance enrollment before and after treatment initiation. The primary outcome was the incidence and risk of serious infections requiring hospitalization. We used stabilized inverse probability of treatment weighting (IPW) based on multinomial propensity scores to balance baseline patient and disease characteristics. Comparative risk of serious infections was assessed through Cox proportional hazards models incorporating stabilized weights.

Results

A total of 9,430 UC patients were included (mean age: 47.5 ± 17.7 years; 49.2% female; 50% on concomitant corticosteroids), followed for a mean duration of 2.3 ± 0.8 years. The incidence rates (IR) per 100 person-years of serious infections were: TNF antagonists (n = 4,111; IR: 6.08 [5.47; 6.70]), vedolizumab (n = 3,165; IR: 5.03 [0.44; 5.65]), IL-12/23 or IL-23 antagonists (n = 1,342; IR: 4.25 [3.34; 5.21]), S1PR modulators (n = 111; IR: 5.17 [1.03; 10.34]) and JAK inhibitors (n = 701; IR: 4.09 [2.79; 5.49]). Risk of serious infections was lower with JAK inhibitors and IL-12/23, or IL-23 antagonists compared to TNF antagonists, and lower with IL-12/23 or IL-23 antagonists compared to vedolizumab. Hazard ratios are represented in the table 1.

Table 1: Risk of serious infections in patients with ulcerative colitis taking advanced biological therapies

Conclusion

In this large real-world cohort of UC patients, initiation with newly developed efficaeous agents like JAK inhibitors and drugs inhibiting the IL-23 pathway was associated with a lower risk of serious infection compared to TNF antagonists.

Disclosure

CM: Consulting fees from AbbVie, Alimentiv, Amgen, AVIR Pharma Inc, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Forte Biosciences, Fresenius Kabi, Gilead, Janssen, McKesson, Mirador Therapeutics, Mylan, Pendopharm, Pfizer, Prometheus Biosciences Inc., Roche, Sanofi, Takeda, Tillotts Pharma; speaker's fees from AbbVie, Amgen, AVIR Pharma Inc, Alimentiv, Bristol Myers Squibb, Eli Lilly, Ferring, Fresenius Kabi, Janssen, Merck, Organon, Pendopharm, Pfizer, Sanofi, Takeda, Tillotts Pharma; royalties from Springer Publishing; research support from AbbVie, Eli Lilly, Ferring, Pfizer.
VJ: Consulting/advisory board fees from AbbVie, Alimentiv Inc, Arena pharmaceuticals, Asahi Kasei Pharma, Asieris, Astra Zeneca, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Flagship Pioneering, Fresenius Kabi, Galapagos, GlaxoSmithKline, Genentech, Gilead, Janssen, Merck, Mylan, Pandion, Pendopharm, Pfizer, Protagonist, Prometheus, Reistone Biopharma, Roche, Sandoz, Second Genome,Takeda, Teva, Topivert, Ventyx, Vividion; speaker’s fees from, Abbvie, Ferring, Galapagos, Janssen Pfizer Shire, Takeda, Fresenius Kabi
SS: Research grants from Pfizer